JP2004536615A - 抗原提示細胞、その調製方法およびその癌ワクチンのための使用 - Google Patents

抗原提示細胞、その調製方法およびその癌ワクチンのための使用 Download PDF

Info

Publication number
JP2004536615A
JP2004536615A JP2003517263A JP2003517263A JP2004536615A JP 2004536615 A JP2004536615 A JP 2004536615A JP 2003517263 A JP2003517263 A JP 2003517263A JP 2003517263 A JP2003517263 A JP 2003517263A JP 2004536615 A JP2004536615 A JP 2004536615A
Authority
JP
Japan
Prior art keywords
cells
pbmc
cell
adhapi
cta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003517263A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536615A5 (cg-RX-API-DMAC7.html
Inventor
リタ・デ・サンティス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of JP2004536615A publication Critical patent/JP2004536615A/ja
Publication of JP2004536615A5 publication Critical patent/JP2004536615A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/59—Lectins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2003517263A 2001-07-30 2002-07-25 抗原提示細胞、その調製方法およびその癌ワクチンのための使用 Pending JP2004536615A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IT2001/000419 WO2003012085A1 (en) 2001-07-30 2001-07-30 Antigen presenting cells, method for their preparation and their use for cancer vaccines
PCT/IT2002/000488 WO2003012086A1 (en) 2001-07-30 2002-07-25 Antigen presenting cells, method for their preparation and their use for cancer vaccines

Publications (2)

Publication Number Publication Date
JP2004536615A true JP2004536615A (ja) 2004-12-09
JP2004536615A5 JP2004536615A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=11133712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003517263A Pending JP2004536615A (ja) 2001-07-30 2002-07-25 抗原提示細胞、その調製方法およびその癌ワクチンのための使用

Country Status (16)

Country Link
US (3) US20030119187A1 (cg-RX-API-DMAC7.html)
EP (1) EP1412485B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004536615A (cg-RX-API-DMAC7.html)
KR (1) KR100916670B1 (cg-RX-API-DMAC7.html)
CN (1) CN100591762C (cg-RX-API-DMAC7.html)
AT (1) ATE505533T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002334387B2 (cg-RX-API-DMAC7.html)
BR (1) BR0211520A (cg-RX-API-DMAC7.html)
CA (1) CA2453522C (cg-RX-API-DMAC7.html)
DE (1) DE60239741D1 (cg-RX-API-DMAC7.html)
DK (1) DK1412485T3 (cg-RX-API-DMAC7.html)
ES (1) ES2367256T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0401753A3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000885A (cg-RX-API-DMAC7.html)
PL (1) PL211907B1 (cg-RX-API-DMAC7.html)
WO (2) WO2003012085A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514455A (ja) * 2007-01-03 2010-05-06 サイトヴァック エイ／エス 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン
JP2016501838A (ja) * 2012-10-30 2016-01-21 メイ ファーマ, インク.Mei Pharma, Inc. 併用療法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
ES2382332T3 (es) * 2003-02-06 2012-06-07 Aduro Biotech Listeria atenuada para entrar en células no fagocíticas, vacunas que comprenden esta listeria y métodos de uso de las mismas
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
AU2004224425B2 (en) * 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
DE10329240A1 (de) * 2003-06-24 2005-01-20 Epigenomics Ag Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
JP4779067B2 (ja) * 2004-01-20 2011-09-21 愛知県 ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途
WO2005075646A1 (ja) * 2004-02-03 2005-08-18 Kurume University ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2007011693A2 (en) 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CN102762719A (zh) * 2009-12-08 2012-10-31 威尔森沃尔夫制造公司 用于过继细胞疗法的细胞培养的改进方法
KR102020939B1 (ko) * 2011-07-07 2019-09-11 리서치 캔서 인스티튜트 오브 아메리카 암 치료 시스템, 방법 및 제형
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
JP6038921B2 (ja) 2011-08-30 2016-12-07 アステックス ファーマシューティカルズ インコーポレイテッド デシタビン誘導体製剤
US9562219B2 (en) * 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
JP2018515421A (ja) * 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造
MX2018000016A (es) 2015-07-02 2019-01-31 Otsuka Pharma Co Ltd Composiciones farmaceuticas liofilizadas.
CN105132371B (zh) * 2015-07-24 2016-05-25 北京鼎成肽源生物技术有限公司 体外提呈、激活dc细胞的方法及其应用
US10052372B2 (en) * 2016-05-24 2018-08-21 Tessa Therapeutics Pte Ltd T cell expansion
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
MX2020001233A (es) 2017-08-03 2020-07-20 Otsuka Pharma Co Ltd Compuesto farmaceutico y metodos de purificacion del mismo.
CN107557333B (zh) * 2017-10-16 2018-07-31 北京鼎成肽源生物技术有限公司 一种用于细胞治疗的新抗原呈递细胞的制备方法
US12213958B2 (en) 2017-11-17 2025-02-04 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR102319259B1 (ko) 2019-07-26 2021-10-28 정재웅 지반천공기용 확장리더 안전제어장치
WO2021027057A1 (zh) * 2019-08-15 2021-02-18 成都冕康生物科技有限公司 一种针对ebv病毒抗原的b细胞疫苗及其制备方法
CN114099655A (zh) * 2021-11-16 2022-03-01 苏州大学 一种预防或治疗癌症的疫苗系统及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030523A2 (en) * 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
EA003832B1 (ru) * 1997-09-15 2003-10-30 Дженетик Иммьюнити, Ллс. Ген-доставочный комплекс для чрескожной доставки чужеродного генетического материала в антиген-презентирующие клетки и способы его использования
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
JPN6008017464, Ｊｐｎ．Ｊ．Ｃａｎｃｅｒ Ｒｅｓ．, 1996, Ｖｏｌ．８７, ｐ．７５１−７５６ *
JPN6008017465, Ｃａｎｃｅｒ Ｒｅｓ．, 1994, Ｖｏｌ．５４, ｐ．１７６６−１７７１ *
JPN6008017466, Ｉｍｍｕｎｏｌｏｇｙ, 1999, Ｖｏｌ．９８， Ｎｏ．４, ｐ．５４１−５５０ *
JPN6008017467, Ｉｎｔ．Ｊ．Ｃａｎｃｅｒ, 20000501, Ｖｏｌ．８６， Ｎｏ．３, ｐ．３８５−３９２ *
JPN6008017468, Ｃｌｉｎ．Ｉｍｍｕｎｏｌ．Ｉｍｍｕｎｏｐａｔｈｏｌ．, 1986, Ｖｏｌ．３９, ｐ．４３１−４４１ *
JPN6008017469, Ｂｉｏｌ．Ｃｈｅｍ．, 200104, Ｖｏｌ．３８２, ｐ．５０７−５２０ *
JPN6008017470, Ｊ．Ｅｘｐ．Ｍｅｄ．, 1995, Ｖｏｌ．１８２, ｐ．６８９−６９８ *
JPN6009053453, Ｊ．Ｃｌｉｎ．Ｉｎｖｅｓｔ．, 1997, Ｖｏｌ．１００， Ｎｏ．１１, ｐ．２７５７−２７６５ *
JPN6009053456, Ｅｘｐ．Ｃｅｌｌ Ｒｅｓ．, 1986, Ｖｏｌ．１６６, ｐ．５４３−５５２ *
JPN6009053475, Ｊ．Ｉｍｍｕｎｏｔｈｅｒ．, 2001, Ｖｏｌ．２４， Ｎｏ．２, ｐ．１５１−１６１ *
JPN6009053477, Ｃｌｉｎ．Ｃａｎｃｃｅｒ Ｒｅｓ．, 1996, Ｖｏｌ．２, ｐ．１６１９−１６２５ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010514455A (ja) * 2007-01-03 2010-05-06 サイトヴァック エイ／エス 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン
JP2016501838A (ja) * 2012-10-30 2016-01-21 メイ ファーマ, インク.Mei Pharma, Inc. 併用療法

Also Published As

Publication number Publication date
KR100916670B1 (ko) 2009-09-08
EP1412485A1 (en) 2004-04-28
BR0211520A (pt) 2004-09-14
US7883889B2 (en) 2011-02-08
WO2003012085A1 (en) 2003-02-13
HK1068913A1 (zh) 2005-05-06
KR20040021662A (ko) 2004-03-10
MXPA04000885A (es) 2004-06-03
CN1537161A (zh) 2004-10-13
US20030119187A1 (en) 2003-06-26
US20050002920A1 (en) 2005-01-06
EP1412485B1 (en) 2011-04-13
AU2002334387B2 (en) 2007-10-04
CN100591762C (zh) 2010-02-24
CA2453522A1 (en) 2003-02-13
DE60239741D1 (de) 2011-05-26
HUP0401753A3 (en) 2011-04-28
HUP0401753A2 (hu) 2004-11-29
WO2003012086A1 (en) 2003-02-13
ES2367256T3 (es) 2011-10-31
ATE505533T1 (de) 2011-04-15
PL367617A1 (en) 2005-03-07
US20040185563A1 (en) 2004-09-23
DK1412485T3 (da) 2011-08-01
PL211907B1 (pl) 2012-07-31
CA2453522C (en) 2013-04-30

Similar Documents

Publication Publication Date Title
CN100591762C (zh) 抗原呈递细胞、其制备方法及其用于癌症疫苗的用途
AU2002334387A1 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
RU2313365C2 (ru) Фармацевтическая композиция для индукции иммунной реакции у человека
Neidhardt-Berard et al. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
JP2002529073A (ja) 三次元装置における造血前駆細胞からのリンパ様組織特異的細胞の生成
JP5706317B2 (ja) 細胞の誘導および促進方法
Kalady et al. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells
CA2354045C (en) New cancer treatments
Osman et al. Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts.
Wang et al. Effect of dendritic cell vaccine against a tongue squamous cell cancer cell line (Tca8113) in vivo and in vitro
Vichchatorn et al. Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme
HK1068913B (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
CN100558400C (zh) 诱导人或动物免疫应答的药物组合物
HK1086750B (en) Pharmaceutical composition for inducing an immune response in a human or animal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080714

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080814

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080916

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100415

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100420

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100827